SG11201401291XA - Adjuvant compound - Google Patents

Adjuvant compound

Info

Publication number
SG11201401291XA
SG11201401291XA SG11201401291XA SG11201401291XA SG11201401291XA SG 11201401291X A SG11201401291X A SG 11201401291XA SG 11201401291X A SG11201401291X A SG 11201401291XA SG 11201401291X A SG11201401291X A SG 11201401291XA SG 11201401291X A SG11201401291X A SG 11201401291XA
Authority
SG
Singapore
Prior art keywords
adjuvant compound
adjuvant
compound
Prior art date
Application number
SG11201401291XA
Other languages
English (en)
Inventor
Ferdinand Antonius Ossendorp
Cornelis Johannes Maria Melief
Selina Khan
Dmitri Viktorovitsj Filippov
Der Marel Gijsbert Arie Van
Original Assignee
Isa Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V filed Critical Isa Pharmaceuticals B V
Publication of SG11201401291XA publication Critical patent/SG11201401291XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201401291XA 2011-10-05 2012-10-04 Adjuvant compound SG11201401291XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (1)

Publication Number Publication Date
SG11201401291XA true SG11201401291XA (en) 2014-05-29

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401291XA SG11201401291XA (en) 2011-10-05 2012-10-04 Adjuvant compound

Country Status (16)

Country Link
US (2) US9314521B2 (enExample)
EP (1) EP2763697B9 (enExample)
JP (1) JP6099210B2 (enExample)
KR (1) KR102053699B1 (enExample)
CN (1) CN104244976B (enExample)
AU (1) AU2012319265B2 (enExample)
BR (1) BR112014008214B1 (enExample)
CA (1) CA2886631C (enExample)
EA (1) EA030741B1 (enExample)
ES (1) ES2952644T3 (enExample)
IL (1) IL231951B (enExample)
IN (1) IN2014DN03325A (enExample)
MX (1) MX356028B (enExample)
NL (1) NL2007536C2 (enExample)
SG (1) SG11201401291XA (enExample)
WO (1) WO2013051936A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2623979T3 (es) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Síntesis de productos peptídicos que contienen hidantoína
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
AU2014300503B2 (en) 2013-06-28 2018-11-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CA2950863C (en) 2014-06-02 2023-01-17 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
HK1255541A1 (zh) 2015-12-11 2019-08-23 Immatics Biotechnologies Gmbh 用於多种癌症免疫治疗的新型肽和肽组合物
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
AU2017281389B2 (en) 2016-06-20 2024-02-22 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2023505304A (ja) 2019-12-07 2023-02-08 アイエスエー ファーマシューティカルズ ビー.ヴイ. B型肝炎ウイルスに関連する疾患の治療
WO2021156404A2 (en) 2020-02-07 2021-08-12 Isa Pharmaceuticals Treatment of hpv-related diseases
WO2021214297A1 (en) 2020-04-23 2021-10-28 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
JP2024525690A (ja) 2021-07-12 2024-07-12 アイエスエー ファーマシューティカルズ ビー.ヴイ. 複雑な混合物中の改善された物質定量
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
EP4601685A1 (en) 2022-10-13 2025-08-20 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) * 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2380873A1 (en) 1999-06-30 2001-01-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
CN106220721B (zh) 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
EP2468763B1 (en) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
AU2008257791B2 (en) 2007-05-31 2013-03-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
AU2011232421B2 (en) * 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.

Also Published As

Publication number Publication date
EA030741B1 (ru) 2018-09-28
CA2886631A1 (en) 2013-04-11
KR102053699B1 (ko) 2019-12-09
ES2952644T3 (es) 2023-11-02
CN104244976B (zh) 2017-05-31
IL231951B (en) 2019-08-29
EA201490709A1 (ru) 2014-09-30
EP2763697C0 (en) 2023-06-07
CN104244976A (zh) 2014-12-24
AU2012319265A1 (en) 2014-05-22
WO2013051936A9 (en) 2013-09-12
CA2886631C (en) 2019-06-11
NZ623869A (en) 2015-11-27
BR112014008214B1 (pt) 2022-07-05
US20160250325A1 (en) 2016-09-01
EP2763697B1 (en) 2023-06-07
KR20140093673A (ko) 2014-07-28
US9314521B2 (en) 2016-04-19
AU2012319265B2 (en) 2016-10-13
MX356028B (es) 2018-05-09
IN2014DN03325A (enExample) 2015-06-26
JP6099210B2 (ja) 2017-03-22
US20150104473A1 (en) 2015-04-16
MX2014004114A (es) 2014-10-17
NL2007536C2 (en) 2013-04-08
US9770506B2 (en) 2017-09-26
EP2763697B8 (en) 2023-07-12
JP2014530808A (ja) 2014-11-20
IL231951A0 (en) 2014-05-28
EP2763697B9 (en) 2023-10-04
BR112014008214A2 (pt) 2017-06-13
EP2763697A1 (en) 2014-08-13
WO2013051936A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
IL231951A0 (en) Excipients and their use for the preparation of preparations
ZA201401553B (en) Cyclopropaneamine compound
IL233154A0 (en) compounds
GB201106817D0 (en) New compound
GB201106395D0 (en) Compounds
GB201109763D0 (en) Compounds
ZA201306857B (en) Mesogen-containing compounds
GB201106799D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
GB201107197D0 (en) Compounds
GB201122139D0 (en) Compounds
EP2717694A4 (en) NEW COMPOUNDS
EP2708540A4 (en) PYRIMIDO-DIAZEPINONE COMPOUND
GB201122305D0 (en) Novel compound
GB201110938D0 (en) Compounds
GB201105659D0 (en) Compounds
GB201112987D0 (en) Novel compound
GB201104669D0 (en) Compound
GB201118613D0 (en) Compounds
GB201121538D0 (en) Compound
GB201118102D0 (en) Compound
GB201109597D0 (en) Compounds
GB201106262D0 (en) Compounds
GB201109915D0 (en) Compounds
GB201106178D0 (en) Compounds